Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Plos One|June 15, 2016
Whole Gene Capture Analysis of 15 CRC Susceptibility Genes in Suspected Lynch Syndrome PatientsAnne M L Jansen, Marije A Geilenkirchen, Tom van Wezel, et al.
European Journal of Cancer (Oxford, England : 1990)|June 26, 2026
Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery ProtocolFlorentine A J Verbeek, Miguel P Martinez, Ilse A C Spiekman, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2024
Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP)Ilse A C Spiekman, Laurien J Zeverijn, Birgit S Geurts, et al.
The Oncologist|December 18, 2023
Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery ProtocolIlse A C Spiekman, Birgit S Geurts, Laurien J Zeverijn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2024
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery ProtocolKarlijn Verkerk, Tijmen J W T van der Wel, Laurien J Zeverijn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery ProtocolBirgit S Geurts, Laurien J Zeverijn, Lindsay V M Leek, et al.
Scientific Data|April 14, 2022
FAIR Genomes metadata schema promoting Next Generation Sequencing data reuse in Dutch healthcare and researchK Joeri van der Velde, Gurnoor Singh, Rajaram Kaliyaperumal, et al.
JCO Precision Oncology|September 21, 2022
<i>BRAF</i> and <i>NRAS</i> Mutation Status and Response to Checkpoint Inhibition in Advanced MelanomaOlivier J van Not, Willeke A M Blokx, Alfons J M van den Eertwegh, et al.
International Journal of Cancer|July 10, 2023
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trialsLaurien J Zeverijn, Eleonora J Looze, Subotheni Thavaneswaran, et al.
BMC Cancer|March 4, 2023
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumoursBirgit S Geurts, Thomas W Battaglia, J Maxime van Berge Henegouwen, et al.
Pageof 5